We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+11.58%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.54B
AUM Growth
+$196M
Cap. Flow
-$299M
Cap. Flow %
-11.74%
Top 10 Hldgs %
37.92%
Holding
126
New
21
Increased
16
Reduced
23
Closed
19

Top Buys

Rank Stock Value
1
ADPT
Adeptus Health Inc
ADPT
+$38.6M
2
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$38M
3
DBVT
DBV Technologies
DBVT
+$30M
4
HUM icon
Humana
HUM
+$28.3M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$26.7M

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$67.9M
2
SAGE
Sage Therapeutics
SAGE
+$35.7M
3
MCK icon
McKesson
MCK
+$27.5M
4
HTWR
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
+$27.4M
5
AET
Aetna Inc
AET
+$25.9M

Sector Composition

Rank Sector Weight
1 Healthcare 68.67%
2 Financials 3.21%
3 Industrials 0.75%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBT
26
DELISTED
Global Blood Therapeutics, Inc.
GBT
$28.8M 1.13%
1,733,828
+540,017
+45% +$10.9M
GKOS icon
27
Glaukos
GKOS
$9.21B
$28.7M 1.13%
+984,112
New +$22.8M
HUM icon
28
Humana
HUM
$48B
$28.7M 1.13%
+159,500
New +$28.3M
ACOR
29
DELISTED
Acorda Therapeutics
ACOR
$26.3M 1.03%
8,578
– –
LKFT
30
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$25.4M 1%
458,112
+130,486
+40% +$6.56M
AXGN icon
31
Axogen
AXGN
$2.12B
$23.3M 0.91%
3,381,439
– –
CI icon
32
Cigna
CI
$74.5B
$21.9M 0.86%
+171,000
New +$22.6M
MOH icon
33
Molina Healthcare
MOH
$11.7B
$21.8M 0.86%
+436,000
New +$23.3M
LCI
34
DELISTED
Lannett Company, Inc.
LCI
$21.3M 0.84%
+223,898
New +$19.2M
RAD
35
DELISTED
Rite Aid Corporation
RAD
$19.6M 0.77%
130,579
+10,925
+9% +$1.72M
COTV
36
DELISTED
Cotiviti Holdings, Inc.
COTV
$19M 0.75%
+900,079
New +$17.1M
ONCE
37
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$18.8M 0.74%
+368,000
New +$15.7M
ALNY icon
38
Alnylam Pharmaceuticals
ALNY
$35.7B
$18.6M 0.73%
+336,000
New +$21.2M
FPRX
39
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$18.5M 0.73%
448,000
-232,000
-34% -$10.1M
LRMR icon
40
Larimar Therapeutics
LRMR
$384M
$18.3M 0.72%
254,634
– –
ALPN
41
DELISTED
Alpine Immune Sciences Inc
ALPN
$17.2M 0.67%
933,103
– –
AKTX
42
Akari Therapeutics
AKTX
$19.3M
$15.5M 0.61%
1,438
– –
BLUE
43
DELISTED
bluebird bio
BLUE
$14.6M 0.58%
+26,100
New +$14.8M
SEM
44
DELISTED
Select Medical
SEM
$14.3M 0.56%
2,444,248
+1,406,564
+136% +$9.32M
IVTY
45
DELISTED
Invuity, Inc
IVTY
$12.6M 0.5%
1,327,009
– –
TARA icon
46
Protara Therapeutics
TARA
$230M
$12.5M 0.49%
38,801
+7,167
+23% +$2.14M
CTMX icon
47
CytomX Therapeutics
CTMX
$788M
$9.64M 0.38%
943,433
– –
RGNX icon
48
Regenxbio
RGNX
$511M
$9.35M 0.37%
1,169,042
– –
NSTG
49
DELISTED
NanoString Technologies, Inc.
NSTG
$8.5M 0.33%
674,622
+68,400
+11% +$993K
FOMX
50
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$8.14M 0.32%
1,282,058
+333,124
+35% +$2.21M
1
2
3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q2 2016 Portfolio in Review

As of Q2 2016, Deerfield Management held 126 positions worth $2.54B, up 8.3% from $2.35B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Deerfield Management withdrew a net $299M in Q2 2016, closing 19 positions and reducing 23 holdings. Its most notable exit was GSK, an estimated $67.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 70% a quarter earlier, followed by Financials and Industrials.

Against the trend, Deerfield Management opened a new position in Syros Pharmaceuticals, Inc. Common Stock worth $38M.

  • Deerfield Management's largest Q2 2016 buy was Syros Pharmaceuticals, Inc. Common Stock: 209,522 shares worth $38M.
  • Deerfield Management added most to Adeptus Health Inc in Q2 2016, an estimated $38.6M increase.
  • Deerfield Management's biggest Q2 2016 reduction was Aetna Inc, cutting an estimated $25.9M.
  • Deerfield Management fully exited GSK in Q2 2016, selling an estimated $67.9M.
  • Deerfield Management's ten largest holdings make up 38% of its $2.54B portfolio in Q2 2016.
  • Deerfield Management opened 21 new positions and closed 19 in Q2 2016.
  • Deerfield Management's portfolio value rose 8.3% quarter-over-quarter to $2.54B.

Based on Deerfield Management's 13F filing for Q2 2016, filed 15 Aug 2016.